2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injection
2013
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis And Cartilage 2013, 21: 655-667. PMID: 23380251, PMCID: PMC3670115, DOI: 10.1016/j.joca.2013.01.016.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsTotal knee replacementPain reliefMajor toxicityRevision total knee replacementCare sequenceConservative pain managementGuideline-concordant careKnee OA treatmentQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioCorticosteroid injectionKnee OAKnee osteoarthritisPain managementOsteoarthritis drugsKnee replacementDMOADsOA treatmentLife yearsProgressionLife expectancyRelief
2008
Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population
Bae SJ, Paltiel AD, Fuhlbrigge AL, Weiss ST, Kuntz KM. Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population. Value In Health 2008, 11: 110-118. PMID: 18237365, PMCID: PMC3476042, DOI: 10.1111/j.1524-4733.2007.00219.x.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAge FactorsAnti-Asthmatic AgentsAsthmaCost SharingDrug PrescriptionsHealth Services AccessibilityHumansInsurance, Pharmaceutical ServicesMassachusettsMedicaidModels, EconometricNebulizers and VaporizersOutcome Assessment, Health CareState Health PlansTreatment RefusalUnited StatesConceptsFrequent acute exacerbationsAcute exacerbationCopayment increaseHealth outcomesPrescription drug copaymentsLikely health outcomesDrug nonadherenceCorticosteroid useAdult asthmaticsAcute eventDrug utilizationMedicaid populationDrug copaymentsMedicaid beneficiariesPrescription drugsCopaymentsReimbursement ratesFinancial burdenExacerbationTarget populationFirst yearNet savingsOutcomesPharmacyCommonwealth of Massachusetts
2005
Surveillance for isocyanate asthma: a model based cost effectiveness analysis
Wild DM, Redlich CA, Paltiel AD. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occupational And Environmental Medicine 2005, 62: 743. PMID: 16234399, PMCID: PMC1740898, DOI: 10.1136/oem.2004.016147.Peer-Reviewed Original Research
2002
State AIDS Drug Assistance Programs
Johri M, Paltiel A, Goldie S, Freedberg K. State AIDS Drug Assistance Programs. Medical Care 2002, 40: 429-441. PMID: 11961477, DOI: 10.1097/00005650-200205000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsCD4 Lymphocyte CountCost of IllnessCost-Benefit AnalysisDirect Service CostsDisease ProgressionEfficiency, OrganizationalEligibility DeterminationHealth Services AccessibilityHumansInsurance CoverageInsurance, Pharmaceutical ServicesLife ExpectancyMedical AssistanceModels, EconometricOrganizational InnovationQuality-Adjusted Life YearsState Health PlansUnited StatesConceptsQuality-adjusted life yearsLifetime direct medical costsLife yearsDirect medical costsDrug Assistance ProgramsAssistance programsState-transition simulation modelQuality-adjusted life expectancyADAP programEconomic performanceLife expectancyMedical costsCost-effective useLifetime costsCost dataServices Utilization SurveyState policyAIDS CostState AIDSCoverage variesComprehensive policyUtilization SurveyPolicyCare resourcesPessimistic assumptions
1997
Estimating CE Ratios under Second-order Uncertainty
Stinnett AA, Paltiel AD. Estimating CE Ratios under Second-order Uncertainty. Medical Decision Making 1997, 17: 483-489. PMID: 9343807, DOI: 10.1177/0272989x9701700414.Peer-Reviewed Original ResearchThe Cost-Effectiveness of HIV Testing
Paltiel AD, Kaplan EH. The Cost-Effectiveness of HIV Testing. Medical Decision Making 1997, 17: 490-495. PMID: 9343808, DOI: 10.1177/0272989x9701700415.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesHealth PolicyHIV InfectionsHIV SeroprevalenceHumansMass ScreeningModels, EconometricUnited StatesConceptsNational surveillance surveyCost-effectiveness estimatesVoluntary HIVHIV testingSeroprevalence studySurveillance SurveyUninfected peopleTesting ratesUninfected individualsHIVInfectionDifferential participationPrevalenceLittle riskParticipation ratesMagnitude of resultsSeronegativesCost drivers
1996
Mathematical programming for the efficient allocation of health care resources
Stinnett A, Paltiel A. Mathematical programming for the efficient allocation of health care resources. Journal Of Health Economics 1996, 15: 641-653. PMID: 10164046, DOI: 10.1016/s0167-6296(96)00493-6.Peer-Reviewed Original ResearchMeSH KeywordsBudgetsCost-Benefit AnalysisDecision MakingHealth Care RationingModels, EconometricProgram EvaluationSocial JusticeUnited StatesConceptsGeneral mathematical programming frameworkMathematical programming frameworkMathematical programmingOptimization techniquesRestrictive assumptionsProgramming frameworkExplicit identificationEfficient allocationResource allocation processConstraintsBudget constraintsAllocation processAllocationProgrammingAssumptionEconomic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy
Villari P, Fattore G, Siegel J, Paltiel A, Weinstein M. Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy. International Journal Of Technology Assessment In Health Care 1996, 12: 336-357. PMID: 8707505, DOI: 10.1017/s0266462300009673.Peer-Reviewed Original ResearchConceptsIntravenous drug usersEarly treatmentDrug usersHIV testing programsLife expectancyEffective early treatmentLow prevalence scenariosHealth care interventionsYears of lifeCost-effectiveness analysisHIV testingAsymptomatic subjectsCare interventionsPrevalence areasHigh prevalenceEconomic evaluationCost-effective procedureHIVPrevalenceTreatmentMore evidenceBehavior changeExpectancyCost savingsCohort